DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
email sent successfully
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
Horizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth Drivers
Horizon Therapeutics plc announced today that it is increasing the peak U.S. annual net sales expectations for its key growth drivers KRYSTEXXA and teprotumumab, as well as providing several pipeline updates.
“As we enter 2020, Horizon is in its strongest position ever,” said Timothy Walbert, chairman, president and chief executive officer, Horizon. “We believe KRYSTEXXA and teprotumumab each has the potential for more than $1 billion in peak U.S. annual net sales. In addition, our strong balance sheet allows us to augment our pipeline to bolster long-term growth. Furthermore, we are evaluating ways to help more patients benefit from our medicines, including two new pipeline programs – one that explores more convenient delivery for KRYSTEXXA by significantly reducing infusion time, and the other for an additional indication for teprotumumab, specifically for the rare disease, diffuse cutaneous scleroderma.”
News & MeetingsFDA Approves First Treatment for Thyroid Eye Disease (Teprotumumab)The U.S. Food and Drug Administration (F...
News & MeetingsA Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye DiseasePrior clinical trials of TEPEZZA(TM) hav...
News & MeetingsClinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presen...Horizon Therapeutics plc today announced...
News & MeetingsTeprotumumab Significantly Improves Proptosis in Thyroid eye DiseasePatients with thyroid eye disease treate...
News & MeetingsHorizon Pharma plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active ...Horizon Pharma plc today announced topli...
News & MeetingsFDA Committee Unanimously Recommends Approval of Teprotumumab for Thyroid Eye DiseaseThe Dermatologic and Ophthalmic Drugs Ad...
Evidence & EducationEarly Experience With Teprotumumab for Chronic Thyroid Eye DiseasePurpose: To report the first case of a ...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.